SELLAS Life Sciences Group (SLS) disclosed updates to severance arrangements for its top three executives in a Securities and Exchange Commission filing on Tuesday, with changes taking effect the same day, and shares jumped nearly 13% on Thursday. The amendments provide protection to executives in case the company gets acquired or undergoes a change in control. Sellas is focused on developing therapies for acute myeloid leukemia and has two key candidates in its pipeline.
CEO Receives Limited Amendment to Employment Agreement
Dr. Angelos Stergiou, president and chief executive officer, received a limited amendment to his existing employment agreement dated July 1, 2019. The only change allows certain change-in-control severance payments to be made in a single lump sum rather than over time. All other terms of his agreement remain unchanged.
CFO and CDO Enter New Severance and Change of Control Agreements
John Burns, senior vice president and chief financial officer, and Dragan Cicic, senior vice president and chief development officer, each entered into new, amended, and restated severance and change of control letter agreements. The terms are identical for both executives.
If either executive is terminated without cause or resigns for good reason outside a change of control, the company will continue base salary for nine months and pay a pro-rata portion of the target annual bonus over the same period according to normal payroll practices.
In the event of termination in connection with a change of control, the executive will receive a lump-sum payment equal to 15 months of base salary plus the full target annual bonus. The company will further accelerate vesting of all unvested equity awards.
Retail Traders Express Bullish Sentiment on Stocktwits
On Stocktwits, retail sentiment around SLS stock stayed within the 'bullish' territory over the past 24 hours, while message volume jumped from 'normal' to 'high' levels.
A Stocktwits user opined that the company announcement hints at ongoing buyout negotiations. Another rejoiced at the stock hitting double digits in intraday trading, though it pulled back after. A third user also voiced hopes for a merger, acquisition, buyout, or a similar transaction.
Company Pipeline Includes Two AML Therapy Candidates
Sellas is focused on developing therapies for acute myeloid leukemia. Its lead candidate, galinpepimut-S (GPS), is currently in a pivotal late-stage trial as a maintenance treatment for certain AML patients. The event-driven study is nearing completion, with final analysis expected soon.
The company's second asset, SLS009, has shown positive results in a completed mid-stage study in relapsed/refractory AML and is now being evaluated in a new randomized mid-stage trial in newly diagnosed AML patients, with topline data anticipated in the fourth quarter of 2026.
According to Koyfin data, both analysts covering SLS rate it 'Buy' or higher. The stock has a 12-month average price target of $10, representing a potential upside of about 9% from the stock's closing price on Wednesday.
SLS stock has gained about 128% year-to-date.
FAQ
What did SELLAS Life Sciences disclose on Tuesday?
SELLAS Life Sciences disclosed updates to severance arrangements for its top three executives in a Securities and Exchange Commission filing on Tuesday, with changes taking effect the same day. The amendments provide protection to executives in case the company gets acquired or undergoes a change in control.
What are the key terms of the new CFO and CDO severance agreements?
If either executive is terminated without cause or resigns for good reason outside a change of control, the company will continue base salary for nine months and pay a pro-rata portion of the target annual bonus. In the event of termination in connection with a change of control, the executive will receive a lump-sum payment equal to 15 months of base salary plus the full target annual bonus, and the company will accelerate vesting of all unvested equity awards.
What is the current status of SELLAS Life Sciences' AML therapy pipeline?
The company's lead candidate, galinpepimut-S (GPS), is in a pivotal late-stage trial as a maintenance treatment for certain AML patients, with final analysis expected soon. The second asset, SLS009, is being evaluated in a randomized mid-stage trial in newly diagnosed AML patients, with topline data anticipated in the fourth quarter of 2026.
